Clinical Trial

A Study of SL-325 in Crohn's Disease Patients

Study acronym: RECEPTIVE-CD1
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.
Trial Details
NCT Number NCT07753850
Lead Sponsor Shattuck Labs, Inc.
Conditions Crohn's Disease
Enrollment 232 participants
Start Date 2026-10
Primary Completion 2028-07 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-12